Makscientific LLC
Burlington, MA
- UEI
- J2NHTDAJGK24
- CAGE
- 3YVL5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 151 S Bedford St Ste 104-B, Burlington, MA 01803, USA
- Website
- makscientific.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| A CB1 antagonist for treatment of kidney disease - other project information - unit 7 - summary/abstract chronic… | National Institute of Diabetes and Digestive and Kidney Diseases | $1,145,486 | |
| Dual fatty acid amide hydrolase (faah)/monoacylglycerol lipase (magl) inhibitors for cannabis use disorder (CUD). -… | National Institute on Drug Abuse | $375,000 | |
| Dual fatty acid amide hydrolase (faah) and monoacyglycerol lipase (magl) inhibitors as novel agents for treatment of… | National Institute on Drug Abuse | $218,855 | |
| Lead optimization of peripheral CB1 neutral antagonists for renal diseases | National Institute of Diabetes and Digestive and Kidney Diseases | $224,999 | |
| Naaa inhibitors as anti-inflammatory agents, phase II | National Institute of Diabetes and Digestive and Kidney Diseases | $1,292,438 |
About Makscientific LLC
Makscientific LLC is a for-profit limited liability company registered in SAM.gov since 2004, located in Burlington, Massachusetts. The company appears to be a specialized research and development organization focused on pharmaceutical and medical research, with expertise in developing novel molecular compounds targeting specific receptor systems. Their primary business model centers on scientific research and drug development, particularly in the areas of metabolic disorders, neurological conditions, and substance use disorders.
The company has received multiple federal grant awards from prominent research agencies, including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute on Drug Abuse (NIDA). Their recent grant work includes developing peripherally acting CB1 neutral antagonists for treating diabetic kidney disease, with a $1,145,486 grant focused on designing improved analogs of compound AM6588 to address kidney disease complications. Additionally, Makscientific has been involved in research on cannabis use disorder, developing dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitors as potential treatment interventions. The company frequently collaborates with Northeastern University through sub-grant awards, working on projects related to CB1 neutral antagonists for alcohol use disorder and compound development. Their research typically involves sophisticated molecular design, synthesis of novel compounds, and comprehensive testing of potential therapeutic agents across various pharmacological domains.
SBA capabilities narrative
We are a small drug discovery entity specializing in areas of pain, addiction, MS, fibrosis, and other diseases
Quick answers
What is Makscientific LLC's UEI?
Makscientific LLC's Unique Entity ID (UEI) in SAM.gov is J2NHTDAJGK24.
What is Makscientific LLC's CAGE code?
Makscientific LLC's CAGE code is 3YVL5.
What is Makscientific LLC's primary NAICS code?
Makscientific LLC's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Makscientific LLC located?
Makscientific LLC's physical address in SAM.gov is 151 S Bedford St Ste 104-B, Burlington, MA 01803, USA.
Is Makscientific LLC registered in SAM.gov?
Yes. Makscientific LLC's SAM.gov registration is active through August 7, 2027.
What is Makscientific LLC's most recent federal award?
Makscientific LLC's most recent federal grant award is A CB1 antagonist for treatment of kidney disease - other project information - unit 7 - summary/abstract chronic… (R44DK139888), from National Institute of Diabetes and Digestive and Kidney Diseases, on September 1, 2024.
On GovTribe
See Makscientific LLC's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors